511 Therapeutics, Inc. — SEC Form D Filing
511 Therapeutics, Inc. filed an SEC Form D on October 30, 2026, reporting $500K raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 30, 2026
- Amount reported
- $500K
- Round stage
- Pre-seed due to the $500,000 funding round intended for initial preclinical target validation and early lab operations.
- Industry
- Biotechnology
- Website
- https://www.511therapeutics.com
What the company does
Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Patients suffering from refractory genetic and metabolic disorders lack targeted molecular therapies that treat underlying root biological causes rather than managing superficial symptoms.
Solution
511 Therapeutics discovers and develops novel targeted biopharmaceutical therapeutics designed to modify disease pathways and improve long-term patient outcomes.
Why now
Advances in high-throughput genomic screening and computational drug design enable early-stage biotechnology startups to identify high-affinity therapeutic candidates rapidly with minimal initial preclinical capital.
Source: SEC EDGAR Form D filing